TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06344715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SL-T10
Description: A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SL-T10
Description: A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SL-T10
Description: A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SL-T10
Description: A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SL-T10
Description: A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SL-T10
Description: A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: A T-cell growth factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: A T-cell growth factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: A T-cell growth factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: A T-cell growth factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: A T-cell growth factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: A T-cell growth factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An immune check point inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An immune check point inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An immune check point inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An immune check point inhibitor
Study: NCT05170815

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.
Study: NCT05441033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-FHB
Description: This is the group where pregnant women and their spouses listen to the fetal heartbeat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-GIT
Description: This is the group in which the guided imagery technique is applied to pregnant women and their spouses.
Study: NCT05170815

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.
Study: NCT05031949

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy plus Camrelizumab
Description: Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
Study: NCT05912205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: Four cycles of neoadjuvant therapy with Vidiximab (2.0mg/kg) were administered first, followed by bladder sparing therapy using maximized TURBT combined with radiotherapy and chemotherapy. The patient will receive vidiximab combined with local radiotherapy after maximizing TURBT surgery. The subjects received treatment with Vidixitol every two weeks for six consecutive treatment cycles, and simultaneously received 1 month of radiation therapy (SBRT, total dose of bladder irradiation field greater than 50 Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy
Study: NCT04954092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-vac M
Description: The vaccine consists of two components: component I and component II. Component I includes a recombinant adenoviral vector based on human adenovirus serotype 26 carrying the gene for the S-protein of the SARS-CoV-2 virus, component II includes a vector based on human adenovirus serotype 5 carrying the protein S gene of the SARS-CoV-2 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-vac M
Description: The vaccine consists of two components: component I and component II. Component I includes a recombinant adenoviral vector based on human adenovirus serotype 26 carrying the gene for the S-protein of the SARS-CoV-2 virus, component II includes a vector based on human adenovirus serotype 5 carrying the protein S gene of the SARS-CoV-2 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-vac M
Description: The vaccine consists of two components: component I and component II. Component I includes a recombinant adenoviral vector based on human adenovirus serotype 26 carrying the gene for the S-protein of the SARS-CoV-2 virus, component II includes a vector based on human adenovirus serotype 5 carrying the protein S gene of the SARS-CoV-2 virus

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Composition without active ingredients
Study: NCT04589481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intake of 3 different candies against bad breath
Description: Intake of 3 different candies against bad breath on three different days (2-days interval each) after artificially creating a temporary bad breath (by eating of chips and cheese); analysis of breathing during intake of candy both subjectively and objectively
Study: NCT05141552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: In both group, subjects keep blood purification and anti heart failure treatment, including ARNI, RASi, Aldosterone inhibitors and beta receptor blocker.
Study: NCT05650762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cinesteam
Description: Cinnamon-based Secondary dressing
Study: NCT04289428

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care ALT
Description: Point of Care ALT from finger-stick whole blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care ALT
Description: Point of Care ALT from finger-stick whole blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Xpert® HBV DNA point of care assay from dried blood spot
Description: Xpert® HBV DNA point of care assay from dried blood spot

Intervention type: DIAGNOSTIC_TEST
Intervention: Xpert® HBV DNA point of care assay from dried blood spot
Description: Xpert® HBV DNA point of care assay from dried blood spot
Study: NCT04914715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive High Frequency Oscillatory Ventilation
Description: We are planning to use (Medin-CNO) for non-invasive ventilation. This machine has option to deliver NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Invasive Ventilation
Description: Invasive ventilation will be started following endotracheal intubation, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40.
Study: NCT06201273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: This High-Intensity Interval Training (HIIT) program, structured to span 12 weeks, incorporates three sessions per week. Each session comprises 8 to 10 exercise intervals on a cycle ergometer. During these intervals, participants are required to reach an intensity level between 8 and 10 points, based on the modified Borg scale, which ranges from 1 to 10 points. A typical interval involves 1 minute of intensive pedaling, followed by a 2-minute rest period without any activity. To facilitate progressive development, the resistance of the cycle ergometer will be adjusted biweekly to increase the pedaling challenge. Despite these adjustments, participants should consistently maintain their effort intensity within the 8 to 10 point range on the modified Borg scale for each interval.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: This training protocol, spanning a duration of 12 weeks, consists of three weekly sessions. In each session, participants will engage in Elastic Resistance Exercises (ERE) using Theraband CLX elastic bands. The focus will be on both concentric and eccentric contractions, maintaining an intensity level of 8 to 10 as per the OMNI-RES scale. Each exercise will be conducted for 1 minute, followed by a 2-minute rest period. Each exercise will be repeated three times within the session.~The specific exercises include bicep curls, seated horizontal rows, and wide squats. To ensure proper progression and adaptation, the exercise load will be adjusted biweekly. This adjustment will be based on the physiological adaptations of the subjects to the training, aiming to recalibrate the loads to new resistance thresholds and maintain a consistent intensity of 8 to 10 on the OMNI-RES scale for each exercise.
Study: NCT06545383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Neuromuscular Stabilization Exercises
Description: Exercises will last 45 minutes and will be 3 days a week for 6 weeks. Additionally DNS exercises will be performed in 40-minute sessions, 2 days a week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises will last 45 minutes and will be 3 days a week for 6 weeks. Additionally, the control group will be asked to walk at moderate intensity for 40 minutes, 2 days a week, for 6 weeks.
Study: NCT05789277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training program
Description: Conventional training program:~5-10 Repetitions ( 0.5-to 1-min rest);~1. Vertical jumps~2. Multiple forward jumps~3. Running exercises~4. Sprints alternating with slow jogging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric hamstring training
Description: Functional training along with specific eccentric hamstrings exercises i.e., prone hamstring curl, exercise ball (or glider) bridge with curl, Nordic hamstring curl, single leg deadlift. The exercise program comprises 3 sets of 15 repetitions once to twice per day for at least 12 weeks.
Study: NCT06265935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: It will be carried out as a randomized controlled experimental design to determine the fatigue and quality of life of pregnant women with gestational diabetes.
Study: NCT06046677

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04113291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH Diet
Description: 12 Weeks of isocaloric DASH diet \<2300 mg Na/day using meals (lunch, dinner, snacks) prepared by the Wake Forest Clinical Research Metabolic Kitchen under the direction of a registered dietician (RD). Participants will prepare their own breakfast from a menu.The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet
Description: 12 weeks usual diet \<2300 mg Na/day
Study: NCT05598060

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
Description: Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
Study: NCT04779762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crohn's disease exclusion diet (CDED)
Description: Dietary therapy for Crohn's disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab Injection [Stelara]
Description: Drug for Crohn's disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab Injection [Stelara]
Description: Drug for Crohn's disease
Study: NCT04700631

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: urinary extracellular vesicle concentration
Description: urinary extracellular vesicle concentration will be determined in urine samples from CRF and healthy patients

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: urinary extracellular vesicle concentration
Description: urinary extracellular vesicle concentration will be determined in urine samples from CRF and healthy patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample in order to determine creatin level

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: blood sample in order to determine creatin level
Study: NCT06514911

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary closure following Laparoscopic cholodochotomy in management of CBD stones
Description: primary closure of cholodochotomy incision in laparoscopic CBD exploration avoiding T-tube insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-tube drainage following Laparoscopic cholodochotomy in management of CBD stones
Description: drainage of bile by T-tube insertion in laparpscopic CBD exploration
Study: NCT05169593

Intervention type: DRUG
Group type: OTHER
Intervention: Biological Drug
Description: Biological therapy used in daily clinical practice in patients with Crohn's disease to prevent disease recurrence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biological Drug
Description: Biological therapy used in daily clinical practice in patients with Crohn's disease to prevent disease recurrence
Study: NCT06143592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training is performed using POWERbreathe® (Powerbreathe, POWERbreathe International Ltd.Warwickshire, England) with a working range of 10-90 cmH2O with the inspiratory threshold pressure loading method. The device is given to each participant to use at home, so Gazi University Scientific Research Projects Coordination Unit (BAP) was applied for the supply of the devices. At the end of the session in which the initial evaluations of all participants are made, the participants are told how to work with the device, the resistance levels of the device and the points to be considered during the application. A sample application session is performed with the participants under the supervision of a specialist physiotherapist. Participants are called by the same physiotherapist every two days by phone to ensure their compliance with the training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training is performed using POWERbreathe® (Powerbreathe, POWERbreathe International Ltd.Warwickshire, England) with a working range of 10-90 cmH2O with the inspiratory threshold pressure loading method. The device is given to each participant to use at home, so Gazi University Scientific Research Projects Coordination Unit (BAP) was applied for the supply of the devices. At the end of the session in which the initial evaluations of all participants are made, the participants are told how to work with the device, the resistance levels of the device and the points to be considered during the application. A sample application session is performed with the participants under the supervision of a specialist physiotherapist. Participants are called by the same physiotherapist every two days by phone to ensure their compliance with the training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training is performed using POWERbreathe® (Powerbreathe, POWERbreathe International Ltd.Warwickshire, England) with a working range of 10-90 cmH2O with the inspiratory threshold pressure loading method. The device is given to each participant to use at home, so Gazi University Scientific Research Projects Coordination Unit (BAP) was applied for the supply of the devices. At the end of the session in which the initial evaluations of all participants are made, the participants are told how to work with the device, the resistance levels of the device and the points to be considered during the application. A sample application session is performed with the participants under the supervision of a specialist physiotherapist. Participants are called by the same physiotherapist every two days by phone to ensure their compliance with the training.
Study: NCT05684718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100 (300 mg)
Description: Intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Oral solution
Study: NCT04781413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-PTX, Sintilimab, S-1
Description: This is a single-arm study with all patients receiving these three drugs.
Study: NCT05597787

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Connect
Description: online education and clinical skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project ECHO for HIV Prevention
Description: education and clinical skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ECHO for HIV Prevention and Stigma Reduction
Description: education, clinical skills and contact
Study: NCT06484920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: 150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg Q3W pembrolizumab
Study: NCT05920720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided Personalized Treatment
Description: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Study: NCT05000931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osia 2 System
Description: Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.
Study: NCT04563039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer
Description: Applaud's Acoustic Enhancer is provided in a lyophilized form. After reconstitution, it is a liquid, containing micron-scale particles that are made of a perfluoroalkane gas core with a lipid shell. The device is intended to be used with cleared/approved pulsed laser systems in fragmenting urinary stones (calculi) in the upper (superior) pole, lower (inferior) pole, and interpolar region of the kidney, pelvis of the kidney, and proximal ureter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ureteroscopic Laser Lithotripsy
Description: Standard of care Ureteroscopic Laser Lithotripsy
Study: NCT04747197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal injection
Study: NCT06194487

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle (50mL) per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAXI Collagen drink
Description: consume 1 bottle (50mL) per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal fish collagen drink
Description: consume 1 bottle (50mL) per day
Study: NCT05435469

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be asked to respond to the demographic information sheet, Adolescent Self-Rating Life Events Check List, Coping Inventory For Stressful Situations, Social Skills Rating System, brief-symptom-inventory, and Wong and Law EI Scale.
Study: NCT06086938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active cTBS combined with iTBS
Description: Daily TBS treatment consists of the following combination: active 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + active 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + active 600-pulse cTBS applied to the SFG in the unaffected hemisphere + active 600-pulses iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of TBS intervention.~The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham cTBS combined with iTBS
Description: Daily sham TBS treatment consists of the following combination: sham 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + sham 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + sham 600-pulse cTBS applied to the SFG in the unaffected hemisphere + 600-pulse sham iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of sham TBS intervention.~The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks.